Wichelhaus Thomas A, Böddinghaus Boris, Besier Silke, Schäfer Volker, Brade Volker, Ludwig Albrecht
Institut für Medizinische Mikrobiologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany.
Antimicrob Agents Chemother. 2002 Nov;46(11):3381-5. doi: 10.1128/AAC.46.11.3381-3385.2002.
Resistance determinants that interfere with normal physiological processes in the bacterial cell usually cause a reduction in biological fitness. Fitness assays revealed that 17 of 18 in vitro-selected chromosomal mutations within the rpoB gene accounting for rifampin resistance in Staphylococcus aureus were associated with a reduction in the level of fitness. There was no obvious correlation between the level of resistance to rifampin and the level of fitness loss caused by rpoB mutations. Among 23 clinical rifampin-resistant S. aureus isolates from six countries, only seven different rpoB genotypes could be identified, whereby the mutation 481His-->Asn was present in 21 (91%) of these 23 isolates. The mutation 481His-->Asn, in turn, which confers low-level rifampin resistance on its own, was not shown to be associated with a cost of resistance in vitro. The restriction to distinct mutations that confer rifampin resistance in vivo, as demonstrated here, appears to be determined by the Darwinian fitness of the organisms.
干扰细菌细胞正常生理过程的耐药决定因素通常会导致生物学适应性降低。适应性分析表明,金黄色葡萄球菌中18个体外选择的rpoB基因染色体突变中有17个与利福平耐药性有关,且这些突变与适应性水平降低相关。利福平耐药水平与rpoB突变导致的适应性损失水平之间没有明显的相关性。在来自六个国家的23株临床耐利福平金黄色葡萄球菌分离株中,仅鉴定出七种不同的rpoB基因型,其中23株分离株中有21株(91%)存在481His→Asn突变。反过来,单独赋予低水平利福平耐药性的481His→Asn突变在体外未显示与耐药代价相关。如本文所示,体内赋予利福平耐药性的不同突变的限制似乎由生物体的达尔文适应性决定。